logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2018 – Triple therapy as first-line treatment of BRAF-mutant advanced melanoma: combination matters

Combination pembrolizumab (pembro)+dabrafenib (D) and trametinib (T) showed promising efficacy and a manageable side-effects profile in melanoma patients with BRAF-mutant advanced disease naïve to treatment